{"@type":"dcat:Dataset","accessLevel":"public","bureauCode":["009:10"],"contactPoint":{"fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"description":"<p>Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (as amended by the Food and Drug Administration Safety and Innovation Act) to notify FDA of a permanent discontinuance of certain drug products, six months in advance, or if that is not possible, as soon as practicable. These drugs include those that are life-supporting, life-sustaining or for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery). The discontinuations provided below reflect information received from manufacturers, and are for informational purposes only.</p>\n","identifier":"642e816a-6a55-492c-a29f-1b7abf5f2fa5","keyword":["cder"],"language":["en"],"license":"http://opendefinition.org/licenses/odc-odbl/","modified":"2016-09-02","programCode":["009:002"],"publisher":{"@type":"org:Organization","name":"Department of Health &amp; Human Services"},"title":"Drugs to be Discontinued"}
